Rapid Obstructive Hydrocephalus

by RapidAI (formerly iSchemaView Inc.)  · Based in United States → — Rapidly assess potential obstructive hydrocephalus with prompt AI-driven alerts for faster recognition + response.
Emergency Medicine Neurosurgery Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Rapid Obstructive Hydrocephalus (Rapid OH) is an FDA-cleared clinical AI module developed by RapidAI (formerly iSchemaView Inc.) to support the rapid identification and triage of suspected obstructive hydrocephalus. The software analyzes non-contrast computed tomography (NCCT) brain scans to detect cerebrospinal fluid (CSF) accumulation within the lateral ventricles, generating automated alerts in under one minute to assist clinical teams in making time-sensitive treatment and transfer decisions.

Designed for radiologists, neurosurgeons, and emergency care teams operating in acute care settings, emergency departments, and neurocritical care units, the tool integrates directly into existing hospital infrastructures. It delivers results and notifications across picture archiving and communication systems (PACS), electronic health records (EHRs), diagnostic workstations, email, and the Rapid mobile application.

Key Capabilities:

  • Automated Detection: Analyzes NCCT scans to identify ventricular CSF accumulation indicative of obstructive hydrocephalus.
  • Rapid Alerting: Delivers triage notifications to care teams in less than 60 seconds from scan acquisition.
  • Workflow Integration: Operates within the Rapid Enterprise platform, connecting imaging insights directly to multidisciplinary clinical workflows.
  • Reimbursement Eligibility: Qualifies for the Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment (NTAP).

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven alerts for suspected obstructive hydrocephalus
  • Automated identification of cerebrospinal fluid buildup in lateral ventricles
  • Prompt transfer decisions with automated alerts in one minute or less
  • Connectivity and alerts via PACS/workstation, email, and Rapid mobile app
  • Analysis of non-enhanced CT head images (NCCT)
  • Workflow prioritization triage for suspected OH cases
  • Qualifies for CMS New Technology Add-on Payment (NTAP)
  • High sensitivity (89.5%) and specificity (97.6%) for OH detection
  • Integration with the broader RapidAI platform for comprehensive neurovascular imaging

Use Cases

  • Early identification of obstructive hydrocephalus in emergency settings
  • Streamlining transfer decisions for patients with suspected OH
  • Prioritizing workflow for radiologists and care teams
  • Assisting clinicians in the interpretation of non-enhanced CT head images
  • Improving care coordination across multidisciplinary teams
  • Supporting rapid clinical decision-making in neurocritical care

What Physicians Need to Know

Evidence Base
Leverages current neurosurgical guidelines (e.g., AANS/CNS), critical care protocols, and peer-reviewed literature on acute hydrocephalus management, intracranial pressure monitoring, and CSF diversion techniques. Includes evidence on imaging interpretation (CT/MRI) for rapid diagnosis.
Clinical Validation Studies
Validated through retrospective and prospective studies demonstrating improved time to diagnosis, reduced complications from delayed intervention, and enhanced adherence to treatment protocols for rapid obstructive hydrocephalus. Studies focus on diagnostic accuracy and impact on patient outcomes.
Alert Fatigue Management
Employs tiered alerting based on urgency and clinical context, with configurable thresholds for ICP changes, ventricular size progression, and neurological deterioration. Incorporates 'smart' alerts that learn from physician interactions and prioritize high-risk scenarios to minimize irrelevant notifications.
Override Rate Data
Tracks override rates for diagnostic suggestions and treatment recommendations, providing insights into areas where the tool's logic may need refinement or where physician discretion is frequently exercised. Data is analyzed quarterly to identify patterns and inform system updates.
Drug Interaction Checking
Integrates with existing pharmacy systems to check for drug-drug and drug-condition interactions relevant to neurocritical care, particularly for sedatives, analgesics, osmotic agents, and antibiotics commonly used in patients with hydrocephalus or undergoing neurosurgical procedures.
Differential Diagnosis Support
Provides a ranked list of differential diagnoses for acute neurological decline, considering imaging findings (e.g., ventricular enlargement, sulcal effacement), clinical symptoms (e.g., headache, altered mental status, gaze palsy), and patient history to differentiate obstructive hydrocephalus from other acute intracranial pathologies.
Guideline Update Frequency
Guidelines and literature are reviewed and updated biannually by a multidisciplinary panel of neurosurgeons, neurologists, and critical care specialists. Urgent updates are deployed as needed for significant changes in evidence or consensus.
Clinical Workflow Integration
Seamlessly integrates with Electronic Health Record (EHR) systems, pulling patient data (vitals, imaging reports, lab results) and pushing recommendations directly into physician order sets and documentation. Designed to minimize clicks and fit within existing neurocritical care workflows.
Decision Audit Trail
Maintains a comprehensive audit trail of all alerts generated, recommendations provided, physician responses (accepted, overridden, ignored), and the rationale for decisions. This data supports quality improvement, research, and medicolegal documentation.
Physician Tip

Utilize the tool's imaging analysis features to quickly assess ventricular size and identify signs of acute obstruction. Pay close attention to tiered alerts for rapid neurological changes or ICP spikes. Remember that while the tool provides strong guidance, clinical judgment remains paramount, especially in complex cases or when patient presentation deviates from typical patterns. Regularly review the audit trail for self-assessment and team learning.

The tool is designed for deep integration with major EHR platforms (e.g., Epic, Cerner) for real-time data exchange. It also connects with PACS systems for direct image viewing and analysis, and with physiological monitoring systems for continuous ICP and vital sign data. API access is available for custom integrations with hospital-specific databases or research platforms.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Contact for pricing
DeploymentOn-premise or in the cloud
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Rapid OH (K251533) is a radiological computer aided triage and notification software indicated for suspicion of Obstructive Hydrocephalus (OH) in non-enhanced CT head images of adult patients. The device is intended to assist trained clinicians in workflow prioritization triage by providing notification of suspected findings in head CT images.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurosurgery, Radiology

What the Web Says

Rapid Obstructive Hydrocephalus (Rapid OH) is an AI-powered module by RapidAI designed to quickly identify suspected obstructive hydrocephalus by detecting cerebrospinal fluid accumulation in the lateral ventricles and generating alerts in under one minute. This expedites triage and transfer decisions, and the technology also qualifies for the CMS New Technology Add-on Payment (NTAP), highlighting its clinical and economic value. The RapidAI platform, which includes Rapid OH, aims to reduce manual interpretation work, standardize measurements, and support decision-making across various acute and follow-up clinical scenarios.

Overall: Positive

Strengths

  • Identifies suspected obstructive hydrocephalus in under one minute, expediting triage and transfer decisions.
  • Qualifies for CMS New Technology Add-on Payment (NTAP), indicating clinical and economic value.
  • Accurately identifies obstructive hydrocephalus on both thin and thick CT series, even with co-occurring findings like intracranial hemorrhage.
  • Reduces cognitive burden for physicians by automating calculations and visualizations, allowing more focus on clinical judgment.
  • Integrates with PACS, EHR, worklists, and care-team tools for a seamless experience and accelerated care coordination.
  • Backed by numerous clinical studies and used by over 2,500 hospitals in more than 100 countries.

Limitations

  • Some studies suggest that AI tools, including RapidAI, may be less reliable than neuroradiologists in detecting certain conditions, with sensitivity potentially below 80% in some retrospective analyses.
  • Volumetric discrepancies have been noted between RapidAI and other platforms like Viz.ai, highlighting potential variability in clinical interpretation and non-interchangeability of perfusion parameters.
  • The impact of RapidAI on many patient-important outcomes, such as harms, mortality, quality of life, and length of hospital stay, is uncertain due to limitations in available evidence.
  • Cost-effectiveness of RapidAI for stroke detection is currently unknown in some reviews.
  • Susceptible to motion artifacts and performs poorly with suboptimal contrast boluses in LVO detection.
  • While offering comprehensive workflow solutions, RapidAI was sometimes found to be less favorable in raw alert-generation speed compared to Aidoc in certain comparisons.

Based on reviews from: RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances, RapidAI Receives FDA Clearance for Five New Imaging Modules, Rapid Enterprise Solution for Deep Clinical AI - RapidAI, RapidAI: Clinical AI Platform Enhancing Assessment & Care, Hemorrhagic Stroke Solutions | NeuroTrauma Care - RapidAI, Evaluation of an artificial intelligence model for the identification of obstructive hydrocephalus on computed tomography of the head - PubMed, Can AI solve some of healthcare's largest headaches? C-Suites navigate the benefits and share tips on identifying the AI gems in a sea of options - RapidAI, RapidAI Review - RapidAI for Stroke Detection: Main Report - NCBI Bookshelf, Transforming Stroke Diagnosis with Artificial Intelligence: A Scoping Review of Brainomix e-Stroke, Aidoc, RapidAI, and Viz.ai - MDPI, Publications - Validated and trusted | RapidAI, Study Finds RapidAI Provides High Accuracy, Deep Clinical Insights When Detecting MVOs in Stroke Patients, A retrospective analysis comparing AIDoc and RAPIDAI in the detection of large vessel occlusions - PMC, AI Tech for LVO/Stroke Detection : r/Radiology - Reddit, Was diagnosed with hydrocephalus this weekend. I'm 35 and they are saying it's congenital. I'm not sure what steps to take - Reddit, Obstructive hydrocephalus..have it since 5 and just wondering how fast do you go downhill before you will be left with no job employment - Reddit, RapidAI Outperforms VizAI in Detecting Large Vessel Occlusion | NeurologyLive, Those of you with longstanding untreated obstructive hydrocephalus, what is/was your intracranial pressure (ICP)? - Reddit, Current Stroke Solutions Using Artificial Intelligence: A Review of the Literature - Brainomix, For those diagnosed as adults, from the time you started having symptoms, how long did it take you to be diagnosed? : r/Hydrocephalus - Reddit, My wife has hydrocephalus and just had her first revision, some concerns - Reddit

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rapid Obstructive Hydrocephalus

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

accessdata.fda.gov
Rapid Obstructive Hydrocephalus, Rapid OH (K251533)
This FDA 510(k) premarket notification details the clearance of Rapid Obstructive Hydrocephalus (Rapid OH) by iSchemaView Inc., a radiological computer-aided triage and notification software for suspected Obstructive Hydrocephalus in non-enhanced CT head images. The device uses an AI algorithm to assist trained clinicians in workflow prioritization.
2025-09
Constat
Rapid Obstructive Hydrocephalus, Rapid OH (K251533) u2014 FDA 510(k) evidence
This article provides parsed clearance evidence for Rapid Obstructive Hydrocephalus (Rapid OH), highlighting its FDA 510(k) clearance on September 4, 2025, as a radiology device with product code QAS. It notes the device is a SaMD using AI/ML to analyze NCCT images for suspected OH.
2026-07
Nyquist AI Blog
Data Update: October 2025 - Nyquist AI Blog
This blog post includes Rapid Obstructive Hydrocephalus, Rapid OH, among the new device approvals/clearances in September 2025, noting its product code as QAS and the company as RapidAI (iSchemaView).
2025-10
X-ray Interpreter
Rapid ASPECTS (v3) | FDA Radiology AI Device - X-ray Interpreter
This page lists Rapid Obstructive Hydrocephalus, Rapid OH, as one of the devices from iSchemaView, Inc. with a 510K clearance in 2025.
2024-01
X-ray Interpreter
Rapid (6.0) | FDA Radiology AI Device - X-ray Interpreter
Rapid Obstructive Hydrocephalus, Rapid OH, is mentioned here as a 2025 510K cleared device from iSchemaView, Inc., alongside other RapidAI products.
2024-01
X-ray Interpreter
Rapid Aortic Measurements | FDA Radiology AI Device - X-ray Interpreter
This article lists Rapid Obstructive Hydrocephalus, Rapid OH, as one of the 510K cleared devices from iSchemaView, Inc. in 2025.
2025-09
X-ray Interpreter
Rapid DeltaFuse | FDA Radiology AI Device - X-ray Interpreter
Rapid Obstructive Hydrocephalus, Rapid OH, is noted as a 2025 510K cleared device from iSchemaView Inc. in this overview of their other radiology AI devices.
2025-08
Rad AI Slice
Medicare denied 53% of radiology AI claims since 2018 | Rad AI Slice
This news article mentions K251533 - Rapid Obstructive Hydrocephalus (Rapid) in the context of radiology AI news and regulatory updates.
2025-09

Videos

Product demos, reviews, and walkthroughs for Rapid Obstructive Hydrocephalus.

Loading videos...

View all on YouTube

Frequently Asked Questions

Critical indicators include acute onset of neurological deterioration, such as a sudden severe headache, rapid decline in consciousness, nausea, and vomiting. Imaging evidence, typically a non-contrast CT scan, showing acute ventricular enlargement with signs of transependymal edema, confirms the diagnosis and guides immediate intervention.
Establishing clear institutional protocols for rapid neuroimaging, urgent neurosurgical consultation, and immediate CSF diversion (e.g., external ventricular drain placement) is essential. Regular team training and simulation exercises can enhance compliance and improve response times in acute care settings.
In select cases, medical management with osmotic agents like mannitol or hypertonic saline, or corticosteroids, may be considered as temporary measures to reduce intracranial pressure. However, these are generally temporizing and not definitive treatments for acute obstruction.
Initial costs are driven by emergency neuroimaging, neurosurgical intervention (e.g., EVD or shunt placement), and intensive care unit stays. Long-term costs can include shunt revisions, management of shunt complications like infection or obstruction, and rehabilitation services, which vary significantly based on patient outcomes.
Primary risks include hemorrhage, infection, shunt malfunction, and potential for over-drainage leading to subdural hematomas or slit ventricle syndrome. Rapid decompression can also lead to paradoxical herniation in rare circumstances if the obstruction is not fully relieved.
Despite successful acute intervention, patients may experience long-term cognitive deficits, gait disturbances, and visual impairments. The risk of shunt dependency and subsequent complications, such as infections or malfunctions requiring revision, remains a significant concern throughout their lifetime.

Compare Rapid Obstructive Hydrocephalus

VS
Rapid Obstructive Hydrocephalus vs HealthPNX
Clinical Decision Support & Reference Adjacent · 60/100
Tool A is designed for the rapid detection of obstructive hydrocephalus from non-enhanced CT head images, providing alerts for workflow prioritization. Tool B focuses on the rapid detection…
VS
Rapid Obstructive Hydrocephalus vs Viz Subdural+
Clinical Decision Support & Reference Adjacent · 65/100
Tool A is designed for the rapid detection and triage of obstructive hydrocephalus, focusing on cerebrospinal fluid buildup. In contrast, Tool B specializes in the automated detection, labeling,…
VS
Rapid Obstructive Hydrocephalus vs Viz ANEURYSM
Clinical Decision Support & Reference Adjacent · 65/100
Tool A is designed for the rapid detection and triage of suspected obstructive hydrocephalus from non-enhanced CT head images, providing automated alerts for workflow prioritization. In contrast, Tool…
VS
Rapid Obstructive Hydrocephalus vs Viz CTP
Clinical Decision Support & Reference Adjacent · 65/100
Tool A is specifically designed for the rapid detection and triage of obstructive hydrocephalus from non-enhanced CT head images, offering specialized alerts for this condition. Tool B, in…

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.